FDA panel backs nocturia treatment

The Panel voted 14-4 to urge that the medication, SER120, be prescribed for certain patients with nocturia, thought as awakening to urinate a couple of times per nighttime. Even the FDA isn’t obliged to follow along with its own advisory panel recommendations, but on average does this. Allergan Is seeking approval to advertise the medicine for regular every day bleeding generally. The panel urged the FDA considers it to get some thinner people of patients that their nocturia is specifically due to an increase in absolute urine volume, a state called nocturnal polyuria.

The Panel made its recommendation based on a subset of patients at the clinical trial that did actually suit the thinner criteria although the organization’s clinical trial wasn’t specifically made to examine this population. Some Panelists described the medication’s effectiveness as little, and just at the dose tested, 1.5 micrograms. They also expressed anxiety doctors can prescribe it , increasing the danger of negative effects, particularly in the older. Desmopressin conveys the danger of hyponatremia, or dangerously lower sodium levels within bloodvessels. Allergan gained exclusive rights to grow and offer the medication from 2010 from independently held Serenity Pharmaceuticals.


Our most popular topics on Managedcaremag.com